Class information for:
Level 1: ANTIPSYCHOTIC POLYPHARMACY//POLYPHARMACY//TUNKU ABDUL RAHMAN NEUROSCI

Basic class information
ID Publications Average number
of references		 Avg. shr. active
ref. in WoS
12342 849 35.6 66%


Bar chart of Publication_year

Last years might be incomplete

Classes in level above (level 2)


ID, lev.
above		 Publications Label for level above
278 18430 RISPERIDONE//CLOZAPINE//OLANZAPINE

Terms with highest relevance score


Rank Term Type of term Relevance score
(tfidf)		 Class's shr.
of term's tot.
occurrences		 Shr. of publ.
in class containing
term		 Num. of
publ. in
class
1 ANTIPSYCHOTIC POLYPHARMACY Author keyword 38 93% 2% 14
2 POLYPHARMACY Author keyword 19 15% 14% 120
3 TUNKU ABDUL RAHMAN NEUROSCI Address 9 55% 1% 12
4 VET ADM C ITOL HEALTHCARE NETWORK VISN 5 Address 9 83% 1% 5
5 PRESCRIPTION PATTERNS Author keyword 7 29% 2% 20
6 ASL PROV BARI Address 6 80% 0% 4
7 SEZ PSICHIAT PSICOL CLIN Address 6 53% 1% 8
8 ANTIPSYCHOTIC COMBINATION Author keyword 3 100% 0% 3
9 SPECIALISED TREATMENT Address 3 100% 0% 3
10 QUAL ASSESSMENT IMPROVEMENT MENTAL HLTH Address 3 50% 0% 4

Web of Science journal categories

Author Key Words


Rank Web of Science journal category Relevance score
(tfidf)		 Class's shr.
of term's tot.
occurrences		 Shr. of publ.
in class containing
term		 Num. of
publ. in
class		 LCSH search Wikipedia search
1 ANTIPSYCHOTIC POLYPHARMACY 38 93% 2% 14 Search ANTIPSYCHOTIC+POLYPHARMACY Search ANTIPSYCHOTIC+POLYPHARMACY
2 POLYPHARMACY 19 15% 14% 120 Search POLYPHARMACY Search POLYPHARMACY
3 PRESCRIPTION PATTERNS 7 29% 2% 20 Search PRESCRIPTION+PATTERNS Search PRESCRIPTION+PATTERNS
4 ANTIPSYCHOTIC COMBINATION 3 100% 0% 3 Search ANTIPSYCHOTIC+COMBINATION Search ANTIPSYCHOTIC+COMBINATION
5 PRESCRIPTION PATTERN 3 28% 1% 8 Search PRESCRIPTION+PATTERN Search PRESCRIPTION+PATTERN
6 COPRESCRIPTIONS 2 67% 0% 2 Search COPRESCRIPTIONS Search COPRESCRIPTIONS
7 TREATMENT RESISTANT SCHIZOPHRENIA 2 14% 1% 11 Search TREATMENT+RESISTANT+SCHIZOPHRENIA Search TREATMENT+RESISTANT+SCHIZOPHRENIA
8 ANTIPSYCHOTIC COMBINATION THERAPY 1 100% 0% 2 Search ANTIPSYCHOTIC+COMBINATION+THERAPY Search ANTIPSYCHOTIC+COMBINATION+THERAPY
9 ANTIPSYCHOTIC PRESCRIPTION 1 100% 0% 2 Search ANTIPSYCHOTIC+PRESCRIPTION Search ANTIPSYCHOTIC+PRESCRIPTION
10 CLOZAPINE AUGMENTATION 1 100% 0% 2 Search CLOZAPINE+AUGMENTATION Search CLOZAPINE+AUGMENTATION

Key Words Plus


Rank Web of Science journal category Relevance score
(tfidf)		 Class's shr.
of term's tot.
occurrences		 Shr. of publ.
in class containing
term		 Num. of
publ. in
class
1 ANTIPSYCHOTIC POLYPHARMACY 66 64% 8% 65
2 REFRACTORY SCHIZOPHRENIA 27 31% 9% 73
3 SULPIRIDE AUGMENTATION 20 100% 1% 9
4 DRUG PRESCRIPTION 20 53% 3% 26
5 CLOZAPINE RISPERIDONE COMBINATION 17 100% 1% 8
6 TREATMENT RESISTANT SCHIZOPHRENIA 14 16% 10% 83
7 CARE PSYCHIATRIC INSTITUTION 14 100% 1% 7
8 AMISULPRIDE AUGMENTATION 12 86% 1% 6
9 POLYPHARMACY 12 13% 10% 82
10 PIMOZIDE AUGMENTATION 9 83% 1% 5

Journals

Reviews


Title Publ. year Cit. Active references % act. ref.
to same field
Critical review of antipsychotic polypharmacy in the treatment of schizophrenia 2014 10 62 69%
Prevalence and correlates of antipsychotic polypharmacy: A systematic review and meta-regression of global and regional trends from the 1970s to 2009 2012 35 143 73%
Antipsychotic Polypharmacy in Schizophrenia Benefits and Risks 2011 39 112 70%
Antipsychotic polypharmacy in psychotic disorders: a critical review of neurobiology, efficacy, tolerability and cost effectiveness 2013 11 70 74%
Interventions to reduce antipsychotic polypharmacy: A systematic review 2013 7 36 78%
Benefits and risks of antipsychotic polypharmacy - An evidence-based review of the literature 2008 35 48 73%
Pharmacological Augmentation Strategies for Schizophrenia Patients With Insufficient Response to Clozapine: A Quantitative Literature Review 2012 31 62 45%
Polypharmacy for schizophrenia 2013 7 33 55%
Safety and tolerability of antipsychotic polypharmacy 2012 21 91 46%
Augmentation of clozapine with a second antipsychotic - a meta-analysis of randomized, placebo-controlled studies 2009 40 19 58%

Address terms


Rank Address term Relevance score
(tfidf)		 Class's shr.
of term's tot.
occurrences		 Shr. of publ.
in class containing
term		 Num. of
publ. in
class
1 TUNKU ABDUL RAHMAN NEUROSCI 9 55% 1.4% 12
2 VET ADM C ITOL HEALTHCARE NETWORK VISN 5 9 83% 0.6% 5
3 ASL PROV BARI 6 80% 0.5% 4
4 SEZ PSICHIAT PSICOL CLIN 6 53% 0.9% 8
5 SPECIALISED TREATMENT 3 100% 0.4% 3
6 QUAL ASSESSMENT IMPROVEMENT MENTAL HLTH 3 50% 0.5% 4
7 SERV PSICHIATR 2 67% 0.2% 2
8 BIPOLAR PSYCHOT DISORDERS CLIN 1 50% 0.2% 2
9 BUR EVIDENCE BASED MED CLIN GUIDELINES 1 100% 0.2% 2
10 DIPARTIMENTO SALUTE MENTALE ASL PROV BARI 1 100% 0.2% 2

Related classes at same level (level 1)


Rank Relatedness score Related classes
1 0.0000269333 CLOZAPINE//RISPERIDONE//OLANZAPINE
2 0.0000133127 PALIPERIDONE PALMITATE//LONG ACTING RISPERIDONE//OLANZAPINE PAMOATE
3 0.0000118958 COCHRANE IZOPHRENIA GRP//WARM SUPPLEMENTING KIDNEY YANG//SURG DEV SCI
4 0.0000106744 GRP PSYCHOSOMAT REHABIL//PARTICIPATION DISORDERS//WORKPLACE PHOBIA
5 0.0000088781 POST PSYCHOTIC DEPRESSION//CALGARY DEPRESSION RATING SCALE//DEPRESSION IN SCHIZOPHRENIA
6 0.0000081062 REDUCED HALOPERIDOL//BROMPERIDOL//REDUCED BROMPERIDOL
7 0.0000079507 9 HYDROXYRISPERIDONE//NORCLOZAPINE//PALIPERIDONE
8 0.0000076484 ACUTE AGITATION//INHALED LOXAPINE//INTRAMUSCULAR HALOPERIDOL
9 0.0000070810 CLINICAL GLOBAL IMPRESSIONS SCALE//FUNCTIONAL REMISSION//SYMPTOMATIC REMISSION
10 0.0000067229 OLANZAPINE//WEIGHT GAIN//SERIOUS MENTAL ILLNESS